Gu, MA
April Z. Gu, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20140202964 | ANTIMICROBIAL POLYCATIONIC SAND FILTER FOR WATER DISINFECTION - A composition comprised of sand and a hydrophobic polycationic polymer covalently bonded to the sand is provided. Exemplary polycationic polymer are N,N-hexyl, methyl-PEI or N,N-dodecyl, methyl-PEI. This antimicrobial polycationic sand filter uses the antimicrobial properties of hydrophobic polycations (N-hexylated polyethylenimine). The sand filter inactivates microorganisms, as water is run through the sand. Preliminary sand washing methods can be used regenerate the inactivation efficacy. Unlike traditional water disinfectants, the polycationic sand filter does not create harmful disinfection byproducts and does not require large chemical and energy consumption. | 07-24-2014 |
Baohua Gu, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100267805 | TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF SINGLE-STRANDED VIRUSES BY RNAI - The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses. | 10-21-2010 |
Bo Gu, North Andover, MA US
Patent application number | Description | Published |
---|---|---|
20090016388 | LASER PROCESSING OF CONDUCTIVE LINKS - A laser system for processing conductive link structures includes a seed laser generating a seed laser beam. The seed laser is sliced by a modulator into a user configurable series of pulses and the pulses are optically amplified and applied to a conductive link structure. Preferably, the bandwidth of the seed laser is less than 1 nm with an IR center frequency, and the frequency of the laser light of the pulses is doubled or quadrupled prior to application to the conductive structure. Preferably, the pulses are about 1-18 second pulsewidth and are separated by 100-400 ns. | 01-15-2009 |
20100237051 | METHOD AND SYSTEM FOR LASER PROCESSING TARGETS OF DIFFERENT TYPES ON A WORKPIECE - A method and system for laser processing targets of different types on a workpiece are provided. The method includes setting a laser pulse width of one or more laser pulses to selectively provide one or more laser output pulses having one or more set pulse widths based on a first type of target to be processed. The method further includes setting a pulse shape of the one or more output pulses to selectively provide the one or more output pulses having the set pulse shape based on the types of targets to be processed. The method still further includes delivering the one or more output pulses having the one or more set pulse widths and the set pulse shape to at least one target of the first type. The method finally includes resetting the laser pulse width of one or more laser pulses to selectively provide one or more laser output pulses having one or more reset pulse widths based on a second type of target to be processed. | 09-23-2010 |
20110062127 | LASER-BASED METHOD AND SYSTEM FOR REMOVING ONE OR MORE TARGET LINK STRUCTURES - Laser-based methods and systems for removing one or more target link structures of a circuit fabricated on a substrate includes generating a pulsed laser output at a predetermined wavelength less than an absorption edge of the substrate are provided. The laser output includes at least one pulse having a pulse duration in the range of about 10 picoseconds to less than 1 nanosecond, the pulse duration being within a thermal laser processing range. The method also includes delivering and focusing the laser output onto the target link structure. The focused laser output has sufficient power density at a location within the target link structure to reduce the reflectivity of the target link structure and efficiently couple the focused laser output into the target link structure to remove the target link structure without damaging the substrate. | 03-17-2011 |
20120083049 | SYSTEM AND METHOD FOR LASER PROCESSING AT NON-CONSTANT VELOCITIES - A method is disclosed for on-the-fly processing at least one structure of a group of structures with a pulsed laser output, The method includes the steps of relatively positioning the group of structures and the pulsed laser output axis with non-constant velocity, and applying the pulsed laser output to the at least one structure of the group of structures during the step of relatively positioning the group of structures and the pulsed laser output axis with non-constant velocity. | 04-05-2012 |
20120195331 | LASER PROCESSING OF CONDUCTIVE LINKS - A laser system for processing conductive link structures includes a seed laser generating a seed laser beam. The seed laser is sliced by a modulator into a user configurable series of pulses and the pulses are optically amplified and applied to a conductive link structure. Preferably, the bandwidth of the seed laser is less than 1 nm with an IR center frequency, and the frequency of the laser light of the pulses is doubled or quadrupled prior to application to the conductive structure. Preferably, the pulses are about 1-18 nanosecond pulsewidth and are separated by 100-400 nanoseconds. | 08-02-2012 |
Bo Gu, Andover, MA US
Patent application number | Description | Published |
---|---|---|
20090321396 | Method And System For High-Speed Precise Laser Trimming And Scan Lens For Use Therein - A method, system and scan lens for use therein are provided for high-speed, laser-based, precise laser trimming at least one electrical element along a trim path. The method includes generating a pulsed laser output with a laser, the output having one or more laser pulses at a repetition rate. A fast rise/fall time, pulse-shaped q-switched laser or an ultra-fast laser may be used. Beam shaping optics may be used to generate a flat-top beam profile. Each laser pulse has a pulse energy, a laser wavelength within a range of laser wavelengths, and a pulse duration. The wavelength is short enough to produce desired short-wavelength benefits of small spot size, tight tolerance, high absorption and reduced or eliminated heat-affected zone (HAZ) along the trim path, but not so short so as to cause microcracking. In this way, resistance drift after the trimming process is reduced. | 12-31-2009 |
Chenghua Gu, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20160120893 | METHODS AND COMPOSITIONS RELATING TO MODULATION OF THE PERMEABILITY OF THE BLOOD BRAIN BARRIER - Described herein are methods and compositions relating to modulating the permeability of the blood-brain barrier, e.g. increasing or decreasing the permeability of the blood-brain barrier for therapeutic purposes. | 05-05-2016 |
Chong-Hui Gu, Waban, MA US
Patent application number | Description | Published |
---|---|---|
20130224293 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N—[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 08-29-2013 |
20140235705 | FORMULATIONS OF THIOPHENE COMPOUNDS - A pharmaceutical composition comprises: a) polymorphic form M or tromethamine salt of Compound (1) represented by the following structural formula: | 08-21-2014 |
20140255483 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 09-11-2014 |
20150024047 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 01-22-2015 |
20150246031 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 09-03-2015 |
Daqing Gu, Burlington, MA US
Patent application number | Description | Published |
---|---|---|
20080247370 | Training Signals for Selecting Antennas and Beams in Mimo Wireless Lans - A computer implemented method selects antennas in a multiple-input, multiple-output wireless local area network that includes multiple stations, and each station includes a set of antennas. Multiple consecutively transmitted sounding packets are received in a station. Each sounding packet corresponds to a different subset of the set of antennas. A channel matrix is estimated from the multiple consecutively transmitted sounding packets, and a subset of antennas is selected according to the channel matrix. | 10-09-2008 |
20090086690 | Method for Selecting Antennas and Beams in MIMO Wireless LANs - A computer implemented method selects antennas in a multiple-input, multiple-output wireless local area network that includes multiple stations, and each station includes a set of antennas. Multiple consecutively transmitted sounding packets are received in a station. Each sounding packet corresponds to a different subset of the set of antennas. A channel matrix is estimated from the multiple consecutively transmitted sounding packets. A frame including a high throughput (HT) control field is sent to initiate a selecting of antennas, and a subset of antennas is selected according to the channel matrix. | 04-02-2009 |
20090290563 | Antenna/Beam Selection Training in MIMO Wireless LANs with Different Sounding Frames - A method selects antennas in a multiple-input, multiple-output (MIMO) wireless local area network (WLAN) that includes a plurality of stations, and each station includes a set of antennas. Plural consecutive packets, received at a station, include plural consecutive sounding packets. Each sounding packet corresponds to a different subset of the set of antennas, and at least one of the plural consecutive packets includes a high throughput (HT) control field including a signal to initiate antenna selection and a number N indicative of a number of sounding packets which follow the at least one packet including the HT control field and which are to be used for antenna selection. A channel matrix is estimated based on a characteristic of the channel as indicated by the received N sounding packets, and a subset of antennas is selected according to the channel matrix. Station and computer program product embodiments include similar features. | 11-26-2009 |
20100176929 | Efficient Protocol for Reverse Direction Data Transmission - A method, system, and computer program product for wireless communication between an initiator station and a responder station. The method includes assigning a transmit window having a predefined window duration to the initiator; sending a request-to send signal (S | 07-15-2010 |
Feng Gu, Westford, MA US
Patent application number | Description | Published |
---|---|---|
20100307377 | Inkjet ink compositions comprising modified pigments - The present invention relates to an inkjet ink composition comprising a liquid vehicle and a modified pigment, which comprises the reaction product of a non-modified pigment and at least one reagent having the formula H | 12-09-2010 |
20120056149 | METHODS FOR ADJUSTING THE CONDUCTIVITY RANGE OF A NANOTUBE FABRIC LAYER - Methods for adjusting and/or limiting the conductivity range of a nanotube fabric layer are disclosed. In some aspects, the conductivity of a nanotube fabric layer is adjusted by functionalizing the nanotube elements within the fabric layer via wet chemistry techniques. In some aspects, the conductivity of a nanotube fabric layer is adjusted by functionalizing the nanotube elements within the fabric layer via plasma treatment. In some aspects, the conductivity of a nanotube fabric layer is adjusted by functionalizing the nanotube elements within the fabric layer via CVD treatment. In some aspects, the conductivity of a nanotube fabric layer is adjusted by functionalizing the nanotube elements within the fabric layer via an inert ion gas implant. | 03-08-2012 |
20160075880 | Modified Colorants and Inkjet Ink Compositions Comprising Modified Colorants - The present invention relates to a modified colorant comprising a colorant having attached at least one organic group. Various embodiments of the organic group are disclosed. For each of these embodiments, preferably the organic group has a defined calcium index value. Also disclosed are various uses for these modified colorants, including inkjet ink compositions. | 03-17-2016 |
Frank X. Gu, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100015068 | Methods and Compositions For Altering Biological Surfaces - Compositions, methods and kits are provided for altering the properties of a biological surface using particles such as, for instance, calcium based particles in combination with an agent that binds to the biological surface. Properties such as color, sheen, texture, strength, and odor of biological surfaces such as teeth and bone are alterable. | 01-21-2010 |
20100022680 | Microfluidic Synthesis of Organic Nanoparticles - The present invention provides microfluidic systems and methods for the production of particles (e.g., nanoparticles) for drug delivery. The present invention provides microfluidic devices useful for production of particles by nanoprecipitation. The present invention provides highly homogenous compositions of particles produced by inventive microfluidic devices. | 01-28-2010 |
George Y. Gu, Burlington, MA US
Patent application number | Description | Published |
---|---|---|
20090302431 | METHOD OF ACCESSING SEMICONDUCTOR CIRCUITS FROM THE BACKSIDE USING ION-BEAM AND GAS-ETCH - The invention generally relates to semiconductor device processing, and more particularly to methods of accessing semiconductor circuits from the backside using ion-beam and gas-etch to mill deep vias through full-thickness silicon. A method includes creating a pocket in a material to be etched, and performing an isotropic etch of the material by flowing a reactive gas into the pocket and directing a focused ion beam into the pocket. | 12-10-2009 |
20100080446 | INLINE LOW-DAMAGE AUTOMATED FAILURE ANALYSIS - A system and method for failure analysis of devices on a semiconductor wafer is disclosed. The present invention comprises the use of an inline focused ion beam milling tool to perform milling and image capturing of cross sections of a desired inspection point. The inspection points are located by identifying at least one fiducial that corresponds to an X-Y offset from the desired inspection point. The fiducials are recognized by a computer vision system. By automating the inspection process, the time required to perform the inspections is greatly reduced. | 04-01-2010 |
20100151679 | SYSTEM FOR MODIFYING SMALL STRUCTURES - A charge transfer mechanism is used to locally deposit or remove material for a small structure. A local electrochemical cell is created without having to immerse the entire work piece in a bath. The charge transfer mechanism can be used together with a charged particle beam or laser system to modify small structures, such as integrated circuits or micro-electromechanical system. The charge transfer process can be performed in air or, in some embodiments, in a vacuum chamber. | 06-17-2010 |
George Y. Gu, Andover, MA US
Patent application number | Description | Published |
---|---|---|
20110068002 | ION EXCHANGE MEMBRANES - Highly energy efficient electrodialysis membranes having low operating costs and a novel process for their manufacture are described herein. The membranes are useful in the desalination of water and purification of waste water. They are effective in desalination of seawater due to their low electrical resistance and high permselectivity. These membranes are made by a novel process which results in membranes significantly thinner than prior art commercial electrodialysis membranes. The membranes are produced by polymerizing one or more monofunctional ionogenic monomers with at least one multifunctional monomer in the pores of a porous substrate. | 03-24-2011 |
20140166488 | ION EXCHANGE MEMBRANES - Highly energy efficient electrodialysis membranes having low operating costs and a novel process for their manufacture are described herein. The membranes are useful in the desalination of water and purification of waste water. They are effective in desalination of seawater due to their low electrical resistance and high permselectivity. These membranes are made by a novel process which results in membranes significantly thinner than prior art commercial electrodialysis membranes. The membranes are produced by polymerizing one or more monofunctional ionogenic monomers with at least one multifunctional monomer in the pores of a porous substrate. | 06-19-2014 |
20140183045 | Electrodesalination System and Method - Systems and methods for the desalination of seawater or brackish water for the purpose of obtaining potable water. Systems may include a combination of electrodialysis and electrodeionization modules. The system configuration and process controls may achieve low energy consumption and stable operation. | 07-03-2014 |
20150217234 | ION EXCHANGE MEMBRANES - Highly energy efficient electrodialysis membranes having low operating costs and a novel process for their manufacture are described herein. The membranes are useful in the desalination of water and purification of waste water. They are effective in desalination of seawater due to their low electrical resistance and high permselectivity. These membranes are made by a novel process which results in membranes significantly thinner than prior art commercial electrodialysis membranes. The membranes are produced by polymerizing one or more monofunctional ionogenic monomers with at least one multifunctional monomer in the pores of a porous substrate. | 08-06-2015 |
20150299003 | ELECTRODESALINATION SYSTEM AND METHOD - Systems and methods for the desalination of seawater or brackish water for the purpose of obtaining potable water. Systems may include a combination of electrodialysis and electrodeionization modules. The system configuration and process controls may achieve low energy consumption and stable operation. | 10-22-2015 |
20150344332 | ELECTROCHEMICAL SEPARATION SYSTEMS AND METHODS - Systems and methods for treating water may involve a first electrochemical separation module that includes at least one ion exchange membrane having a first set of performance characteristics, and a second electrochemical separation module that includes at least one ion exchange membrane having a second set of performance characteristics that is different than the first set of performance characteristics. Performance characteristics may relate to at least one of water loss, electrical resistance, and permselectivity. Staged treatment systems and methods may provide improved efficiency. | 12-03-2015 |
Guiru Gu, Lowell, MA US
Patent application number | Description | Published |
---|---|---|
20140291479 | Backside Configured Surface Plasmonic Structure For Infrared Photodetector And Imaging Focal Plane Array Enhancement - The invention relates to quantum dot and photodetector technology, and more particularly, to quantum dot infrared photodetectors (QDIPs) and focal plane array. The invention further relates to devices and methods for the enhancement of the photocurrent of quantum dot infrared photodetectors in focal plane arrays. | 10-02-2014 |
Jessie Gu, Framingham, MA US
Patent application number | Description | Published |
---|---|---|
20100240760 | Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent - A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty-eight polymorphisms were examined in twelve genes from the renin-angiotensin-aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant associations were seen between one polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the angiotensin II type 2 receptor (AGTR2) gene, and clinical parameters of mean sitting diastolic and systolic blood pressure decrease. These effects were not found with irbesartan and placebo treatment, but instead were specific to aliskiren treatment. | 09-23-2010 |
Jessie Gu, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150320725 | Use of Organic Compound for the Treatment of Noonan Syndrome - The use of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Noonan Syndrome, a method of treating a warm-blooded animal, especially a human, having Noonan Syndrome, comprising administering to said animal a therapeutically effective amount of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition and a commercial package comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a package insert or other labeling including directions for treating Noonan Syndrome. | 11-12-2015 |
Jessie Gu, Frammingham, MA US
Patent application number | Description | Published |
---|---|---|
20140134262 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS - The present invention provides a compound of Formula I: | 05-15-2014 |
Jian-Qiao Gu, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140088067 | TAZOBACTAM ARGININE COMPOSITIONS - This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions. | 03-27-2014 |
20140163048 | COMPOSITIONS WITH INCREASED STABILITY FOR INHIBITING TRANSIENT RECEPTOR POTENTIAL ION CHANNEL TRPA1 - This disclosure describes solid forms of the compound of Formula (I) and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain. | 06-12-2014 |
20140187528 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 07-03-2014 |
20140206659 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 07-24-2014 |
20140213567 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 07-31-2014 |
20140275001 | CRYSTALLINE FORM OF A BETA-LACTAMASE INHIBITOR - This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions. | 09-18-2014 |
20150072957 | Tazobactam Arginine Compositions - This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions. | 03-12-2015 |
20150306076 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 10-29-2015 |
Jije Gu, Shrewsbury, MA US
Patent application number | Description | Published |
---|---|---|
20100074900 | PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 03-25-2010 |
Jijie Gu, Shewsbury, MA US
Patent application number | Description | Published |
---|---|---|
20100028359 | ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products. | 02-04-2010 |
20130149313 | ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products. | 06-13-2013 |
Jijie Gu, Shrewsbury, MA US
Patent application number | Description | Published |
---|---|---|
20100087436 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION - Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed. | 04-08-2010 |
20110034368 | Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and Proteolysis - Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. The primary product can also contain cleavage sequences such as other proteolytic cleavage or protease recognition sites, or signal peptides which contain recognition sequences for signal peptidases, separating at least two of the multiple protein subunits. The sequences of the inserted auto-processing polypeptides or cleavage sites can be manipulated to enhance the efficiency of expression of the separate multiple protein subunits. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins. Where the polyprotein contains immunoglobulin heavy and light chain segments or fragments capable of antigen recognition, in an embodiment a selectable stoichiometric ratio is at least two copies of a light chain segment per heavy chain segment, with the result that the production of properly folded and assembled functional antibody is made. Modified signal peptides, including such from immunoglobulin light chains, are described. | 02-10-2011 |
20110117079 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 05-19-2011 |
20110212094 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 09-01-2011 |
20110217237 | THERAPEUTIC DLL4 BINDING PROTEINS - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 09-08-2011 |
20120201746 | HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF - The invention provides compositions, methods, and kits related to half-Ig binding proteins that include a functional antibody binding site and a CH3 domain wherein the CH3 domain includes at least one mutation to inhibit CH3-CH3 dimerization. | 08-09-2012 |
20120258108 | Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 10-11-2012 |
20130195871 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-01-2013 |
20130243789 | Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and Proteolysis - Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins. | 09-19-2013 |
20140093521 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 04-03-2014 |
20140134172 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 05-15-2014 |
20140186377 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF - The present invention encompasses prostaglandin E | 07-03-2014 |
20140213770 | HIGH-THROUGHPUT ANTIBODY HUMANIZATION - The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation. | 07-31-2014 |
20140213772 | CROSS-OVER DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONSTRUCTS - Engineered cross-over DVD-Ig binding proteins that bind to two or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
20140221622 | MONOVALENT BINDING PROTEINS - Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-07-2014 |
20140235476 | MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS FOR IDENTIFYING VARIANTS OF SAME - Provided are protein, nucleic acid, and cellular libraries of multivalent binding proteins (e.g., DVD-Fab or DVD-Ig molecules) and the use of these libraries for the screening of multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-21-2014 |
20140271458 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 09-18-2014 |
20140308286 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 10-16-2014 |
20140348835 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 11-27-2014 |
20140356281 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 12-04-2014 |
20150017095 | PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 01-15-2015 |
20150344590 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17 - Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 12-03-2015 |
20160031986 | Therapeutic DLL4 Binding Proteins - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 02-04-2016 |
20160060332 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 03-03-2016 |
20160122439 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 05-05-2016 |
Jinming Gu, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100028899 | CELL CYCLE PHASE MARKERS - The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle. | 02-04-2010 |
Jinming Gu, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20110275697 | REGULATION OF CYCLIN D - The present invention provides methods for modulating the level or activity of cyclin D by inhibiting EGLN2 expression or activity. The methods are particularly useful for treating or preventing a disorder associated with elevated cyclin D levels or activity, such as cancer. | 11-10-2011 |
Jjijie Gu, Shrewsbury, MA US
Patent application number | Description | Published |
---|---|---|
20100040537 | Prostaglandin E2 Binding Proteins and Uses Thereof - The present invention encompasses prostaglandin E | 02-18-2010 |
Lei Gu, Chelmsford, MA US
Patent application number | Description | Published |
---|---|---|
20130179917 | Multi-Component Advertising Campaigns - A computerized method, system and computer program product for implementing a multi-component advertising campaign, respectively comprising steps, structure and instructions for defining data representing a multi-component advertising campaign, the data specifying one or more campaign instructions, each of the campaign instructions identifying a multi-component advertisement and targeted digital media having a plurality of advertising opportunities, each advertising component of the multi-component advertisement corresponding to a respective one of the plurality of advertising opportunities; receiving an advertising request from a requesting device during presentation of the targeted digital media; selecting one of the campaign instructions from the multi-component advertising campaign corresponding to the targeted digital media; and transmitting information for inserting the multi-component advertisement identified in the selected campaign instruction into the plurality of advertising opportunities of the targeted digital media. | 07-11-2013 |
Lei Gu, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140035438 | Passive, Self-Tuning Energy Harvester for Extracting Energy From Rotational Motion - Energy harvester. The harvester includes a radially extending beam having a proximal end mounted a selected distance from an axis of rotation of an object and includes a mass at its distal end. The mass, beam characteristics, and the selected distance are chosen so that the beam resonant frequency during rotation of the object substantially matches the driven rotational frequency of the object. | 02-06-2014 |
20140238103 | PRESSURE SENSOR WITH INTEGRATED HEALTH MONITORING AND COMPENSATION - A pressure sensor may measure gas or liquid pressure. A chamber may have an inlet that receives the gas or liquid. A flexible diaphragm may be within the chamber that has a surface exposed to the gas or liquid after it flows through the inlet. A pressure sensor system may sense changes in the flexible diaphragm caused by changes in the pressure of the gas or liquid. A pressure-insensitive sensor system may sense changes in the flexible diaphragm that are not caused by changes in the pressure of the gas or liquid. The pressure-insensitive sensor system may be insensitive to changes in the flexible diaphragm caused by changes in the pressure of the gas or liquid. | 08-28-2014 |
20140298884 | SELF-CALIBRATING PRESSURE SENSOR SYSTEM WITH PRESSURE SENSOR AND REFERENCE SENSOR THAT SHARE COMMON SEALED CHAMBER - A self-calibrating pressure sensor system may measure the pressure of a gas or liquid. The system may include a pressure sensor, a reference sensor, and a drift compensation system. The pressure sensor may include a pressure-sensing flexible diaphragm with one side exposed to the gas or liquid and another side forming a wall of a sealed chamber. The reference sensor may include a reference flexible diaphragm that has two sides that are both within or exposed to the same sealed chamber. The drift compensation system may produce information that is indicative of the pressure of the gas or liquid based on the signal from the pressure sensor, and compensate for drift in this signal based on changes in the signal from the reference sensor. The pressure-sensing flexible diaphragm and the reference flexible diaphragm may be made at substantially the same time by depositing or growing a single layer of material in a single continuous step. | 10-09-2014 |
20140318656 | MEMS PRESSURE SENSORS WITH INTEGRATED BAFFLES - A pressure sensor system may sense the pressure of a gas or liquid. The system may include a housing that has an entry port for the gas or liquid; a pressure sensor within the housing; and a baffle positioned between the entry port and the pressure sensor. The baffle may have one or more inlets oriented to receive gas or liquid that enters the entry port; one or more outlets oriented to deliver the received gas or liquid to the pressure sensor; and one or more sealed flow channels that prevent the gas or liquid from escaping from the baffle, other than through the one or more outlets. At least one of the outlets may be located within no more than one millimeter of a location on the pressure sensor. The pressure sensor and baffle may be made at the same time during a process of depositing, pattering, etching, wafer bonding, and/or wafer thinning a series of layers using microelectromechanical systems (MEMS) technology. | 10-30-2014 |
20150276536 | Micro-Pirani Vacuum Gauges - Micro-Pirani gauge vacuum gauges are described that use low-thermal conductivity support elements. A micro-Pirani gauge or vacuum sensor can include a heating element operative to heat a gas and to produce a signal corresponding to the pressure of the gas; a platform configured to receive the heating element, with the platform having a first coefficient of thermal conductivity; and a support element connected to a substrate and configured to support the platform with the heating element within an aperture disposed in the substrate, with the support element having a second coefficient of thermal conductivity, where the second coefficient of thermal conductivity is less than the first coefficient of thermal conductivity. Multimode pressure sensing including a micro-Pirani gauge are also described. | 10-01-2015 |
Liangcai Gu, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20110091952 | METHOD FOR ENZYMATIC PRODUCTION OF DECARBOXYLATED POLYKETIDES AND FATTY ACIDS - Disclosed herein are methods of preparing alkenes from beta-hydroxy or beta-sulfate carboxylic acid or carboxylic acid derivatives using thioesterase and optionally a sulfotransferase. | 04-21-2011 |
Luo Gu, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150359928 | VISCOELASTIC HYDROGELS WITH FAST STRESS RELAXATION - Provided are fast relaxing hydrogels that are useful for regulating cell behavior and enhancing tissue regeneration, e.g., bone regeneration. | 12-17-2015 |
Shaoting Gu, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20140282785 | CATV VIDEO AND DATA TRANSMISSION SYSTEM WITH DIGITAL INPUT - Improved systems and methods for delivering CATV content over a fiber optic network to a receiver. | 09-18-2014 |
20140282801 | CATV VIDEO AND DATA TRANSMISSION SYSTEM WITH HYBRID INPUT - Improved systems and methods for delivering CATV content over a fiber optic network from a transmitter. | 09-18-2014 |
20140282802 | CATV VIDEO AND DATA TRANSMISSION SYSTEM WITH AUTOMATIC DISPERSION COMPENSATION - Improved systems and methods for delivering CATV content over a fiber optic network from a transmitter by compensating for optical dispersion over the fiber optic network. | 09-18-2014 |
20140282803 | CATV VIDEO AND DATA TRANSMISSION SYSTEM WITH AUTOMATIC PARAMETER CONTROL - Improved systems and methods for delivering CATV content over a fiber optic network from a transmitter. The transmitter preferably monitors performance attributes of a transmitted signal and selectively configures the transmitter based on the monitored attributes. | 09-18-2014 |
20140282804 | CATV VIDEO AND DATA TRANSMISSION SYSTEM WITH RF INPUT - Improved systems and methods for delivering CATV content over a fiber optic network from a transmitter. | 09-18-2014 |
20150020134 | CATV VIDEO AND DATA TRANSMISSION SYSTEM WITH RF AND DIGITAL COMBINING NETWORK - Improved systems and methods for delivering CATV content over a fiber optic network from a transmitter. The transmitter preferably includes a combining network that combines CATV signals received from a CATV head end. | 01-15-2015 |
Shuo Gu, Andover, MA US
Patent application number | Description | Published |
---|---|---|
20150285873 | MONOLITHIC THREE-AXIS MAGNETIC FIELD SENSOR - A three-axis magnetic sensor or magnetometer is provided. Two magnetic sensor Wheatstone bridges using barber pole AMR structures are fabricated on opposite sides of a bump structure formed on a substrate to provide surfaces that are at a pre-determined angle with respect to the flat surface of the substrate. The bridge assembly is oriented along the Y axis and the bridges are interconnected such that Y and Z channel signals can be produced by processing of the bridge signals. The X channel signals are provided by an X axis sensor provided on the level surface of the substrate. | 10-08-2015 |
Ting-Lie Gu, Woburn, MA US
Patent application number | Description | Published |
---|---|---|
20090325189 | Tyrosine phosphorylation sites - The invention discloses 443 novel phosphorylation sites identified in leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 12-31-2009 |
20100015724 | LYSINE ACETYLATION SITES - The invention discloses 332 novel acetylation sites identified in various cancers, peptides (including AQUA peptides) comprising a acetylation site of the invention, antibodies specifically bind to a novel acetylation site of the invention, and diagnostic and therapeutic uses of the above. | 01-21-2010 |
Weifeng Gu, Holden, MA US
Patent application number | Description | Published |
---|---|---|
20150133318 | ENZYMATIC METHOD TO ENRICH FOR CAPPED RNA, KITS FOR PERFORMING SAME, AND COMPOSITIONS DERIVED THEREFROM - The instant invention is based, at least in part, on the identification of novel methods for the enzymatic enrichment of capped RNAs. The invention provides, e.g., methods for enrichment of capped RNAs, kits for making such capped RNAs, and compositions of enriched RNAs or cDNA libraries derived therefrom. | 05-14-2015 |
Wenxin Gu, Concord, MA US
Patent application number | Description | Published |
---|---|---|
20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-05-2012 |
20130345218 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 12-26-2013 |
20140094473 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 04-03-2014 |
20140142119 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 05-22-2014 |
20140296201 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 10-02-2014 |
20150191468 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-09-2015 |
Xiubin Gu, Wilmington, MA US
Patent application number | Description | Published |
---|---|---|
20120021432 | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same - The present invention relates to isolated phosphorylated NF45 peptides and isolated phosphorylation site-specific antibody or antigen-binding portion thereof that specifically binds a phosphorylated NF45 protein. The present invention also relates to methods of utilizing these antibodies to determine the therapeutic efficacy of a candidate compound and methods for screening for candidate compounds that increase the phosphorylation of NF45 protein in a cell. | 01-26-2012 |
Yong Gu, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20090186394 | Crystallizable JNK complexes - The present invention relates to a data storage medium encoded with the corresponding structure coordinates of molecules and molecular complexes which comprise the active site binding pockets of JNK3. A computer comprising such data storage material is capable of displaying such molecules and molecular complexes, or their structural homologues, as a graphical three-dimensional representation on a computer screen. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen and design compounds, including inhibitory compounds, that bind to JNK3 or homologues thereof. This invention also relates to molecules and molecular complexes which comprise the active site binding pockets of JNK3 or close structural homologues of the active site binding pockets. | 07-23-2009 |
20110178069 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds. | 07-21-2011 |
20120165319 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds. | 06-28-2012 |
Yongfeng Gu, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20140157218 | MODEL-BASED RETIMING WITH FUNCTIONAL EQUIVALENCE CONSTRAINTS - A system and method tests for functional equivalence prior to automatically retiming a high-level specification. An Intermediate Representation (IR) includes one or more graphs or trees based on the high-level specification. A functional equivalence (FE) analyzer determines whether one or more components in the graph meet certain value and state conditions and thus is a candidate for retiming. A bounded scheduler then retimes only those components that pass the FE analysis. | 06-05-2014 |
20150178418 | MODEL-BASED RETIMING WITH FUNCTIONAL EQUIVALENCE CONSTRAINTS - A system and method tests for functional equivalence prior to automatically retiming a high-level specification. An Intermediate Representation (IR) includes one or more graphs or trees based on the high-level specification. A functional equivalence (FE) analyzer determines whether one or more components in the graph meet certain value and state conditions and thus is a candidate for retiming. A scheduler can use components that fail FE as a retiming boundary. | 06-25-2015 |
Yu Gu, Amherst, MA US
Patent application number | Description | Published |
---|---|---|
20090190487 | METHOD AND APPARATUS FOR PROVIDING PERFORMANCE MEASUREMENT FOR A NETWORK TUNNEL - A method and apparatus for providing performance measurements on network tunnels in packet networks are disclosed. For example, the method establishes two tunnels between a first measurement host and a first router, and establishes a tunnel between the first router and a second measurement host. The method also establishes a multicast group having a plurality of members, and sends one or more packets addressed to the multicast group from the first measurement host. The method measures the frequencies of directly and/or indirectly received responses from the plurality of members of the multicast group, and provides a plurality of estimated values for a plurality of packet transmission rates from measurement of the frequencies for one or more of said tunnels. | 07-30-2009 |
Yu Gui Gu, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20130274273 | Inhibiting Transient Receptor Potential Ion Channel TRPA1 - This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain. | 10-17-2013 |
20130289012 | 1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 10-31-2013 |
20130296290 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296291 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296292 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296293 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296555 | BETA-LACTAMASE INHIBITORS - Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains. | 11-07-2013 |
20130303504 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-14-2013 |
20130345190 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 12-26-2013 |
20140315876 | BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 10-23-2014 |
20140316133 | BETA-LACTAMASE INHIBITORS - Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains | 10-23-2014 |
20140323459 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 10-30-2014 |
20150025053 | CEPHALOSPORIN COMPOUND - The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., | 01-22-2015 |
20150031659 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 01-29-2015 |
20150031660 | 1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 01-29-2015 |
20150031665 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 01-29-2015 |
20150031666 | 1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 01-29-2015 |
20150038478 | BETA-LACTAMASE INHIBITORS - Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains. | 02-05-2015 |
20150038479 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 02-05-2015 |
20150038482 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 02-05-2015 |
Yu Gui Gu, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20140158116 | INHIBITING TRPA1 FOR THE TREATMENT OF ASTHMA - This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as asthma. | 06-12-2014 |
Zeji Gu, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20080265977 | High isolation electronic multiple pole multiple throw switch - A high isolation electronic multiple pole multiple throw (MPNT) switching device is formed as a ring circuit that includes plural poles, plural throws, plural series switches and plural means for shunting. Each series switch receives a control signal, and each means for shunting receives shunt control signals. In one aspect, the shunt control signals include control signals received by distant series switches. In another aspect, the shunt control signals include control signals received by adjacent series switches. In another aspect, the shunt control signals include signals complementary to signals received by adjacent series switches. In another aspect, the shunt control signals include pole DC potentials or throw DC potentials. In another aspect, a switching device may operate in multiple transmission mode or multiple input multiple output (MIMO) mode. The MPNT switching device provides low insertion loss and high isolation at a wide range of frequencies. | 10-30-2008 |
20090058553 | Non-reflective SPNT switch - A non-reflective SPNT switching device comprises one pole, at least three throws, a plurality of main switches, and a plurality of bridge switches. The bridge switches enable all throws to be non-reflective. Each main switch is coupled between the pole and one of the throws. One main switch has a first (eg ON) state, the one main switch being coupled to an active throw in a conducting signal path, and each other main switch has a second (eg OFF) state. Each throw is operably coupled to first and second adjacent throws through first and second adjacent bridge switches. For the active throw, the first and second bridge switches have the second state. For each non-active throw, one of the adjacent bridge switches has the first (eg ON) state and one of the adjacent bridge switches has the second state. | 03-05-2009 |
20090153222 | Non-reflective MPNT switch - A non-reflective ring topology MPNT switching device comprises at least two poles, at least four throws, plural main switches, and plural bridge switches. The bridge switches enable all throws to be non-reflective throughout a wide frequency range. Each main switch is connected between one of the poles and one of the throws. Each bridge switch is connected between two of the throws, and each throw is connected to at least M+1 of the bridge switches, M being the pole count. In operation, each of M of the main switches has a first (ON) state and is connected to one of M active throws. For each active throw, each bridge switch connected to the active throw has a second (OFF) state. For each non-active throw, one bridge switch connected to the non-active throw has the first (ON) state and each other connected bridge switch has the second (OFF) state. | 06-18-2009 |
Zhen Gu, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150025005 | SELF-REGULATED PEPTIDE HYDROGEL FOR INSULIN DELIVERY - A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia. | 01-22-2015 |
20150030641 | GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY - Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen peroxide, entrapped in or bound to the microgels, wherein the polymeric microgel expands when pH decreases from physiological pH and shrinks when pH increases towards physiological pH, thereby releasing insulin at a rate corresponding to the glucose concentration. In one embodiment, the glucose oxidase and/or the agent reducing hydrogen peroxide are encapsulated in nanogels, then encapsulated within the microgel. | 01-29-2015 |
20160067190 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT - A system for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through an injectable nano-network consisting of oppositely-charged dextran nanoparticles encapsulating insulin and glucose-specific enzymes forming a gel-like 3D scaffold. As demonstrated by the examples, the system effectively dissociates to release insulin in a hyperglycemic condition, where the catalytic conversion of glucose into gluconic acid and the subsequent degradation of polymeric matrix are facilitated. This formulation design provides a delivery strategy for both self-regulated and long-term diabetes management. | 03-10-2016 |
Zhenya Gu, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150278828 | MARKET ANALYSIS FOR AN ONLINE BUSINESS - A method for performing a market analysis for a first online business is disclosed. Market information for a plurality of online businesses may be collected. A user may request a market analysis for the first online business. Market information for the first online business may also be collected. The marketing information for the plurality of online businesses and the first online business may be canonicalized to make comparisons easier. One or more online businesses in the plurality of online businesses may be selected as being similar to the first online business. The marketing information for the first online business may be compared to the marketing information of the similar one or more online businesses. The results of the comparison may be displayed to the user. The user may request modifications to the first online business. The first online business may be modified and the modified online business may be published. | 10-01-2015 |
Zhiyong Gu, North Chelmsford, MA US
Patent application number | Description | Published |
---|---|---|
20120015211 | METHODS FOR THE FABRICATION OF NANOSTRUCTURES - The present invention relates to methods of fabricating nanostructures using a replacement reaction. In a preferred embodiment, metal particles in an inert atmosphere undergo a replacement reaction to form a layer on the metal particle which is removed to form a high surface area nanostructure. A preferred embodiment includes the fabrication of heater elements, powders and heater assemblies using the nanostructures. | 01-19-2012 |
Zhiyong Gu, Chelmsford, MA US
Patent application number | Description | Published |
---|---|---|
20120132644 | METHODS FOR THE FABRICATION OF NANOSTRUCTURES HEATING ELEMENTS - The present invention relates to methods of fabricating nanostructures using a replacement reaction. In a preferred embodiment, metal particles in an inert atmosphere undergo a replacement reaction to form a layer on the metal particle which is removed to form a high surface area nanostructure. A preferred embodiment includes the fabrication of heater elements, powders and heater assemblies using the nanostructures. | 05-31-2012 |